Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

Solid Biosciences shares were up 50% to $6.06 after the company said it saw positive initial data from a Phase 1/2 trial evaluating SGT-003, a gene therapy product candidate intended for the treatment ...

The trial data, which was reported on February 18, 2025, also suggested potential cardiac benefits from the therapy. The company mentioned that SGT-003 has been well-tolerated with no serious adverse ...

Shares of Solid Biosciences (NASDAQ ... early results from a Phase 1/2 trial for its lead asset SGT-003 in Duchenne muscular dystrophy, a genetically driven muscle disorder. SGT-003 is designed ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...

Shares of Solid Biosciences (NASDAQ:SLDB) jumped ~88% in the premarket on Tuesday after the gene therapy developer reported ...

Duchenne Muscular Dystrophy (DMD) is caused by a lack ... but it is possible they could raise their expectations significantly. Solid Biosciences' recent results are highly encouraging for its ...